CD274 and neoplasm: A pilot clinical trial to assess the clinical efficacy of a canine chimeric monoclonal antibody targeting PD-L1 in canine oral malignant melanoma or undifferentiated sarcoma showed a reduced tumour burden in some dogs, with the survival of dogs with metastatic oral malignant melanoma being prolonged in the antibody treatment group (n = 4) compared to an historical control group (n = 15) treated by standard therapies [118].